Samuel R, Knight SR, Adams R, Das P, Dorth J, Finch D, Guren MG, Hawkins MA, Moug S, Rajdev L, Sebag-Montefiore D, Renehan AG, Fish R, plus the CORMAC-2 collaborators (2024)
International consensus to define outcomes for trials of chemoradiotherapy for anal cancer (CORMAC-2): defining the outcomes from the CORMAC core outcome set
EClinicalMedicine, 78, 102939
DOI 10.1016/j.eclinm.2024.102939, PubMed 39720423

Mala T, Abelseth BK, Al-Haidari G, Dørum LMR, Hatlevoll I, Rekstad LC, Stenvold H, Øvrebø KK, Aahlin EK (2024)
[Not Available]
Tidsskr Nor Laegeforen, 144 (15)
DOI 10.4045/tidsskr.24.0547, PubMed 39692659

Lordick F, Mauer ME, Stocker G, Cella CA, Ben-Aharon I, Piessen G, Wyrwicz L, Al-Haidari G, Fleitas-Kanonnikoff T, Boige V, Lordick Obermannová R, Martens UM, Gomez-Martin C, Thuss-Patience P, Arrazubi V, Avallone A, Shiu KK, Artru P, Brenner B, Buges Sanchez C, Chau I, Lorenzen S, Daum S, Sinn M, Merelli B et al. (2024)
Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study
Ann Oncol (in press)
DOI 10.1016/j.annonc.2024.10.829, PubMed 39542422